Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16


A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats.

Moore GL, Bernett MJ, Rashid R, Pong EW, Nguyen DT, Jacinto J, Eivazi A, Nisthal A, Diaz JE, Chu SY, Muchhal US, Desjarlais JR.

Methods. 2019 Feb 1;154:38-50. doi: 10.1016/j.ymeth.2018.10.006. Epub 2018 Oct 23.


Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fcγ receptor IIb inhibitory receptor.

Chu SY, Yeter K, Kotha R, Pong E, Miranda Y, Phung S, Chen H, Lee SH, Leung I, Bonzon C, Desjarlais JR, Stohl W, Szymkowski DE.

Arthritis Rheumatol. 2014 May;66(5):1153-64. doi: 10.1002/art.38334.


Immune suppression in cynomolgus monkeys by XPro9523: an improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRn.

Bernett MJ, Chu SY, Leung I, Moore GL, Lee SH, Pong E, Chen H, Phung S, Muchhal US, Horton HM, Lazar GA, Desjarlais JR, Szymkowski DE.

MAbs. 2013 May-Jun;5(3):384-96. doi: 10.4161/mabs.23976. Epub 2013 Apr 2.


Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody.

Chu SY, Horton HM, Pong E, Leung IW, Chen H, Nguyen DH, Bautista C, Muchhal US, Bernett MJ, Moore GL, Szymkowski DE, Desjarlais JR.

J Allergy Clin Immunol. 2012 Apr;129(4):1102-15. doi: 10.1016/j.jaci.2011.11.029. Epub 2012 Jan 16.


Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.

Tai YT, Horton HM, Kong SY, Pong E, Chen H, Cemerski S, Bernett MJ, Nguyen DH, Karki S, Chu SY, Lazar GA, Munshi NC, Desjarlais JR, Anderson KC, Muchhal US.

Blood. 2012 Mar 1;119(9):2074-82. doi: 10.1182/blood-2011-06-364521. Epub 2012 Jan 13.


A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens.

Moore GL, Bautista C, Pong E, Nguyen DH, Jacinto J, Eivazi A, Muchhal US, Karki S, Chu SY, Lazar GA.

MAbs. 2011 Nov-Dec;3(6):546-57. doi: 10.4161/mabs.3.6.18123. Epub 2011 Nov 1.


Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus.

Horton HM, Chu SY, Ortiz EC, Pong E, Cemerski S, Leung IW, Jacob N, Zalevsky J, Desjarlais JR, Stohl W, Szymkowski DE.

J Immunol. 2011 Apr 1;186(7):4223-33. doi: 10.4049/jimmunol.1003412. Epub 2011 Feb 28.


Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies.

Horton HM, Bernett MJ, Peipp M, Pong E, Karki S, Chu SY, Richards JO, Chen H, Repp R, Desjarlais JR, Zhukovsky EA.

Blood. 2010 Oct 21;116(16):3004-12. doi: 10.1182/blood-2010-01-265280. Epub 2010 Jul 8.


Engineering fully human monoclonal antibodies from murine variable regions.

Bernett MJ, Karki S, Moore GL, Leung IW, Chen H, Pong E, Nguyen DH, Jacinto J, Zalevsky J, Muchhal US, Desjarlais JR, Lazar GA.

J Mol Biol. 2010 Mar 12;396(5):1474-90. doi: 10.1016/j.jmb.2009.12.046. Epub 2010 Jan 4.


Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.

Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R, Desjarlais JR, Zhukovsky EA.

Cancer Res. 2008 Oct 1;68(19):8049-57. doi: 10.1158/0008-5472.CAN-08-2268.


Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies.

Chu SY, Vostiar I, Karki S, Moore GL, Lazar GA, Pong E, Joyce PF, Szymkowski DE, Desjarlais JR.

Mol Immunol. 2008 Sep;45(15):3926-33. doi: 10.1016/j.molimm.2008.06.027. Epub 2008 Aug 8.


Tc-99m Sestamibi Scintimammography for the Evaluation of Breast Masses in Patients with Radiographically Dense Breasts.

Cutrone JA, Khalkhali I, Yospur LS, Diggles L, Weinberg I, Pong EM, Tolmos J, Vargas MP, Vargas HI.

Breast J. 1999 Nov;5(6):383-388.


Class 3 malocclusions.

Pong E.

Ont Dent. 1988 Sep;65(7):23-5. No abstract available.


Some properties of frozen concentrated starters produced by continuous culture.

Lloyd GT, Pong EG.

J Dairy Res. 1973 Jun;40(2):157-67. No abstract available.


Supplemental Content

Support Center